CGNSF (Cognetivity Neurosciences) EBITDA: $-3.03 Mil (TTM As of Oct. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cognetivity Neurosciences EBITDA?

Cognetivity Neurosciences CGNSF -99.00% EBITDA is $-3.03 Mil as of Oct. 2023.

Cognetivity Neurosciences's EBITDA for the three months ended in Oct. 2023 was $-0.51 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Oct. 2023 was $-3.03 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

Cognetivity Neurosciences's EBITDA per Share for the three months ended in Oct. 2023 was $-0.01. Its EBITDA per share for the trailing twelve months (TTM) ended in Oct. 2023 was $-0.04.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

Cognetivity Neurosciences  (OTCPK:CGNSF) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Cognetivity Neurosciences EBITDA Related Terms


Cognetivity Neurosciences EBITDA Historical Data

* Premium members only.

The historical data trend for Cognetivity Neurosciences's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cognetivity Neurosciences EBITDA Chart

Cognetivity Neurosciences Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
EBITDA
Get a 7-Day Free Trial -3.17 -1.98 -1.46 -10.33 -4.76

Cognetivity Neurosciences Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.25 -1.23 -0.72 -0.57 -0.51

CGNSF vs VEEV, GEHC, HQY: EBITDA Comparison

For the Health Information Services subindustry, Cognetivity Neurosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cognetivity Neurosciences EV-to-EBITDA vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cognetivity Neurosciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cognetivity Neurosciences's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Cognetivity Neurosciences's EBITDA for the fiscal year that ended in Jan. 2023 is calculated as

Cognetivity Neurosciences's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Jan. 2023, Cognetivity Neurosciences's EBITDA was $-4.76 Mil.

Cognetivity Neurosciences's EBITDA for the quarter that ended in Oct. 2023 is calculated as

Cognetivity Neurosciences's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Oct. 2023, Cognetivity Neurosciences's EBITDA was $-0.51 Mil.

EBITDA for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of $-3.03 Mil mean?
Cognetivity Neurosciences (CGNSF) has a EBITDA of $-3.03 Mil as of Oct. 2023. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Cognetivity Neurosciences.
Is Cognetivity Neurosciences' EBITDA too high?
Cognetivity Neurosciences' current EBITDA is $-3.03 Mil.
How does Cognetivity Neurosciences' EBITDA compare to VEEV and GEHC?
Cognetivity Neurosciences' EBITDA of $-3.03 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Healthcare Providers & Services company?
A good EBITDA depends on the Healthcare Providers & Services industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Cognetivity Neurosciences. Cognetivity Neurosciences's current EBITDA is $-3.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cognetivity Neurosciences stock overvalued right now?
Cognetivity Neurosciences (CGNSF) has a current EBITDA of $-3.03 Mil. The current EBITDA is $-3.03 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Cognetivity Neurosciences (CGNSF), the current EBITDA is $-3.03 Mil as of Oct. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cognetivity Neurosciences Business Description

Address 800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6
Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.